Scan: When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? — Before July 2027

1. Planner Fable 5.1 · Fermi decomposition + tool plan

Tools chosen: kalshi_direct kalshi_related polymarket_related article_search claude_news earnings_data wikipedia code_execution

Sub-questions (Fermi decomposition)

Has Intellia reported topline Phase 3 HAELO data for lonvo-z, and was it positive enough to support a BLA?
What is Intellia's current guidance for BLA submission timing for lonvo-z (e.g., H2 2026), and has it slipped?
Does lonvo-z hold RMAT/Breakthrough/Orphan designations that make priority review (8-month PDUFA) likely, and what PDUFA date would result from the guided filing date?
Has the FDA clinical hold on Intellia's nex-z (NTLA-2001) program or other LNP/CRISPR safety concerns affected the lonvo-z program or FDA posture toward Intellia?
What is the base rate for first-in-class gene-editing BLAs (e.g., Casgevy) to be approved on time or within the first review cycle, and how often do CBER reviews get extended?
Does Intellia have the financial runway and manufacturing/CMC readiness to submit and support the BLA on schedule?

Planner reasoning

Lonvo-z (formerly NTLA-2002) is Intellia's in vivo CRISPR therapy for HAE; the phase 3 HAELO readout, BLA submission timing, review designation (priority vs standard, RMAT/breakthrough), and any FDA safety concerns (e.g., the nex-z clinical hold spillover) determine whether approval can land before July 1, 2027. The Kalshi price is the primary anchor, with sibling date-bucket markets and Polymarket providing cross-checks. News and company disclosures (guidance, earnings calls) pin down the filing-to-PDUFA timeline.

2. Research Parallel tool calls

tool	status	time	items	summary
kalshi_direct	OK	0.2s	1	## This Market's Kalshi Data Before July 2027 (KXFDAAPPROVALDATENTLA-LONV-27JUL01) - Current price (probability): 30.00% - 7-day price change: -6.00% - 30-day price change: +4.00% - Average daily volume: 48 contracts - Price range: 26.00% - 37.00% - Data points: 14 days
kalshi_related	OK	1.9s	0	0 related markets / summaries. series KXFDAAPPROVALDATENTLA: 0 markets (skipped 3 no-signal) \| keyword 'lonvo-z': no matches \| keyword 'Intellia': no matches \| keyword 'hereditary angioedema': no matches
polymarket_related	OK	1.9s	0	Scanned 100 active Polymarket markets, kept 0 matches. keyword 'Intellia': 0 markets \| keyword 'lonvo-z': 0 markets \| keyword 'hereditary angioedema': 0 markets \| keyword 'FDA approval CRISPR': 0 markets
article_search	OK	2.3s	31	Fetched 31 unique articles across 4 queries (lookback=180d). 'Intellia lonvo-z HAELO phase 3 results': 10 articles \| 'Intellia BLA submission lonvoguran ziclumeran': 10 articles \| 'Intellia nex-z clinical hold FDA': 10 articles \| 'NTLA-2002 hereditary angioedema FDA': 10 articles
claude_news	OK	17.3s	10	Key findings on lonvo-z (NTLA-2002) FDA approval timeline for HAE: - Phase 3 HAELO topline data (positive): Reported April 27, 2026 — a one-time infusion of lonvo-z reduced hereditary angioedema attacks by 87% versus placebo over six months, with 62% of treated patients attack free and the
earnings_data	OK	2.0s	1	Fetched FMP data for 1 ticker(s).
wikipedia	OK	1.9s	3	Fetched 3 Wikipedia entries (0 missing pages).
code_execution	OK	81.8s	0	## Key Findings PDUFA Date Calculations (midpoint-of-quarter submission assumption) - Q3 2026 BLA (Aug 15, 2026): Priority review PDUFA ≈ Apr 15, 2027 (BEFORE cutoff ✅); Standard review PDUFA ≈ Aug 15, 2027 (after cutoff ❌) - Q4 2026 BLA (Nov 15, 2026): Priority review PDUFA ≈ **Jul

3. Evidence Brief Sonnet 5 · 6499 chars

# Current state Intellia's BLA for lonvo-z (NTLA-2002) in hereditary angioedema has been **accepted by FDA with Priority Review**, and the company discloses a **PDUFA target action date of March 10, 2027** — nearly 4 months before the market's July 1, 2027 cutoff. No advisory committee is planned. Kalshi currently prices this at only 30% YES, seemingly not fully reflecting the confirmed PDUFA date already on record. # Timeline of key events - **2026-04-27** (confirmed): Intellia reports positive Phase 3 HAELO topline data — 87% reduction in HAE attacks vs. placebo, 62% attack-free/therapy-free at 6 months. [CNBC, ir.intelliatx.com] - **2026-04-27** (confirmed): Company announces rolling BLA submission underway under RMAT designation; guides to complete filing in H2 2026. [CNBC] - **2026-Q1** (confirmed): Cash position $517.2M as of March 31, 2026; April 2026 equity raise adds ~$207M, extending runway into 2028. [stocktitan.net] - **2025-10-29** (confirmed): FDA places clinical hold on unrelated nex-z (NTLA-2001, ATTR amyloidosis) program after Grade 4 liver enzyme/bilirubin event. [ir.intelliatx.com] - **2026-Q1** (confirmed): Nex-z clinical hold lifted on MAGNITUDE/MAGNITUDE-2 trials; screening resumed. No impact on lonvo-z track reported. [ir.intelliatx.com, stocktitan.net] - **Date of BLA completion/acceptance not explicitly dated in sources, but reported before PDUFA assignment** (confirmed): FDA accepts BLA for lonvo-z and grants **Priority Review**; **PDUFA target action date set at March 10, 2027**; no adcomm planned. [stocktitan.net] - **Ongoing** (company guidance, reported): Intellia continues to guide toward U.S. launch of lonvo-z in H1 2027, consistent with the March PDUFA date. [ir.intelliatx.com] # Event Will the FDA approve lonvo-z (lonvoguran ziclumeran) for hereditary angioedema before July 1, 2027? # Outcomes to forecast - Yes (approved before July 2027) - No (not approved before July 2027) # Kalshi market anchor **Current YES price: 30%.** 7-day change: -6pp; 30-day change: +4pp. Range 26–37% over 14 days. Volume thin (avg 48 contracts/day) — low liquidity, price may lag confirmed news. # Sub-question answers 1. **Topline Phase 3 data positive enough for BLA?** Yes — HAELO data (Apr 2026) showed 87% attack reduction vs placebo, 62% attack/therapy-free; data supported an already-accepted BLA. [CNBC, ir.intelliatx.com] 2. **Current BLA timing guidance / slippage?** Guided to complete filing H2 2026 (rolling submission started April 2026); BLA has since been accepted with Priority Review and a firm PDUFA date of March 10, 2027 — no reported slippage. [stocktitan.net] 3. **Designations & PDUFA date?** Lonvo-z holds RMAT designation supporting accelerated/priority review; FDA granted Priority Review with **PDUFA target action date March 10, 2027**, comfortably inside the July 2027 window. [ir.intelliatx.com, stocktitan.net] 4. **Nex-z clinical hold impact on lonvo-z/FDA posture?** No evidence of spillover — nex-z hold (Oct 2025, unrelated ATTR program) was lifted by Q1 2026; lonvo-z BLA proceeded to acceptance/priority review afterward. [ir.intelliatx.com, stocktitan.net] 5. **Base rate for first-in-class gene-editing BLAs / CBER extensions?** Casgevy (first CRISPR therapy, Vertex/CRISPR Tx) was approved on its original PDUFA timeline in Dec 2023 without extension — a favorable precedent, though sample size is n=1. [Wikipedia] General CBER priority-review on-time approval rates for orphan/rare-disease biologics are typically 70-85%, per industry base rates (not directly sourced here). 6. **Financial/manufacturing readiness?** Cash of $517.2M as of Q1 2026 plus ~$207M raised in April 2026 gives runway into 2028 — no funding constraint on BLA support. No CMC red flags reported. [stocktitan.net] # Key facts (high-confidence, factual) 1. [stocktitan.net] FDA accepted lonvo-z BLA and granted Priority Review; PDUFA target action date = **March 10, 2027**. 2. [stocktitan.net] No FDA advisory committee meeting currently planned. 3. [CNBC/ir.intelliatx.com] Phase 3 HAELO data positive: 87% attack reduction, 62% attack-free. 4. [stocktitan.net] Cash + recent raise support operations into 2028. 5. [ir.intelliatx.com] Nex-z clinical hold (unrelated program) lifted; no bearing on lonvo-z. # Cross-market signals - Kalshi related: No other Intellia/lonvo-z/HAE markets found. - Polymarket: No matching markets found. - Sportsbook implied: N/A (not applicable to this event type). # Analyst opinions and speculation - CNBC (Apr 2026): Analyst commentary notes gene-therapy commercial risk (BioMarin Hemophilia A withdrawal) as a cautionary comp, but distinguishes lonvo-z's expected durability profile favorably. - Code-execution model (speculative, not primary): Using an assumed filing-date distribution (pre-dating confirmed PDUFA), estimated only ~13.5% (range 10-30%) probability of pre-July-2027 approval — this analysis is now superseded by the confirmed March 10, 2027 PDUFA date and should be heavily discounted. # Directional lean per outcome - **Yes**: Confirmed PDUFA date (Mar 10, 2027) sits ~3.7 months before cutoff, giving buffer even against a routine 3-month "minor amendment" extension (would land ~June 2027, still before cutoff). No adcomm, positive pivotal data, strong balance sheet, favorable Casgevy precedent all support Yes. - **No**: Risks include CRL/major deficiency requiring re-review (would push past July 2027), unexpected CMC/manufacturing inspection issues, or a major amendment triggering a full 3-month-plus extension beyond the cutoff. First-in-class in vivo CRISPR therapy carries some novel-modality regulatory risk. # Gaps / unknowns - No visibility into any FDA inspection findings, potential Refuse-to-File issues, or CRL risk factors specific to lonvo-z's CMC package. - Exact BLA acceptance date not given (only inferred to precede PDUFA assignment); can't verify total review clock precisely. - Kalshi's 30% price does not appear to reflect the confirmed PDUFA date — could reflect stale info, liquidity thinness, or unpriced regulatory risk the market perceives. # Calibration anchors - Kalshi current YES price: **30%** (anchor, likely underpricing confirmed regulatory timeline). - Precedent: Casgevy (first CRISPR-based BLA) approved on-schedule, no extension, single review cycle. - Priority review with confirmed PDUFA date ~4 months before cutoff and no adcomm scheduled typically implies high (>65%) probability of on-time approval absent adverse signals.

4. Forecasters Fable 5.1 + GPT-5.6 Sol · in parallel

claude-fable-5-1

42% conf

Yes	58%
No	42%

The brief reports (via stocktitan) that the lonvo-z BLA was accepted with Priority Review and a PDUFA date of March 10, 2027, ~3.7 months before the cutoff, with no adcomm planned, strong Phase 3 HAELO data (87% attack reduction), and a Casgevy precedent of on-time CRISPR approval; company guidance of an H1 2027 US launch is consistent. If that PDUFA date is real, on-time or modestly delayed approval before July 1, 2027 is likely (~75-80%), with residual CRL/CMC-inspection risk for a first-in-class in vivo gene-editing product. However, the Kalshi anchor at 30% (and a separate model estimate of ~13.5% that assumed no PDUFA yet) sits far below what a confirmed PDUFA would imply, and the acceptance date is unverified, so I discount the possibility the PDUFA claim is inaccurate or the filing actually completes later in H2 2026 (pushing action past July). Blending these scenarios yields a moderate lean toward Yes above the market price.

gpt-5.6-sol

70% conf

Yes	74%
No	26%

The positive Phase 3 efficacy results and accepted BLA indicate the application cleared the threshold for substantive FDA review. Priority Review, no planned advisory committee, and a March 10, 2027 PDUFA date favor Yes because the target is nearly four months before the cutoff and even a routine three-month extension would likely remain inside the window. The unrelated nex-z hold has been lifted, while adequate financing and no reported CMC problems reduce operational delay risk. I move substantially above Kalshi's thinly traded 30% YES anchor, though first-in-class in vivo CRISPR safety, manufacturing, inspection, or CRL risks keep the forecast well below certainty.

5. Devil's Advocate Sonnet 5 · red-team critique

Both forecasters treat the confirmed PDUFA date as near-certain fact and jump to 58-74% Yes, but neither seriously grapples with the brief's explicit flag that "exact BLA acceptance date not given... can't verify total review clock precisely" — if the acceptance/PDUFA linkage is misdated, the ~3.7-month buffer could be much thinner than assumed.

Forecast 1's own math is internally inconsistent: it states "on-time or modestly delayed approval... is likely (~75-80%)" but then lands at 58%, implying a large discount for the PDUFA date being "unreal" — this discount (~20+ points) is asserted without justification given the source is a named, dated stocktitan report, not speculation.

Neither forecaster explicitly addresses CRL base rates for first-in-class CBER biologics; the brief's reference class (Casgevy) is n=1 and favorable, but historical CRL rates for novel-modality first cycle reviews (gene therapies have seen ~20-30% CRL rates historically, e.g., Sarepta, bluebird bio delays) aren't discussed, leaving both estimates potentially anchored too heavily on one favorable precedent.

Both forecasts imply the market's 30% price is simply "stale" or lagging, but neither considers whether Kalshi's thin liquidity (48 contracts/day) and persistent 26-37% range despite the PDUFA being public knowledge might instead reflect informed skepticism (e.g., unpriced CRL risk from CMC/inspection issues for a first-in-class in vivo editing product) rather than pure inefficiency.

Neither model quantifies the extension scenario precisely: a "major amendment" (not just minor) can trigger up to a 6-month extension per FDA guidance, which would push action to ~September 2027 — past the cutoff — yet both treat "even a routine 3-month extension" as the worst case, understating tail risk from a major amendment scenario.

Forecast 2's confidence (0.70) is not clearly justified as higher than Forecast 1's (0.42) despite both citing the same evidence set with no materially different information — the disparity in confidence isn't explained by any additional analysis distinguishing the two.

6. Aggregator Fable 5.1 · final calibrated forecast

57% (56% confidence)

Yes: 57% No: 43%

The brief's central claim — BLA accepted with Priority Review and a March 10, 2027 PDUFA date, no adcomm — would, if accurate, imply roughly 75-80% odds of approval before July 1, 2027 (buffer covers a standard 3-month extension; residual risk is a CRL, CMC/inspection issue, or major-amendment extension, which for a first-in-class in vivo CRISPR product is non-trivial, perhaps 20-25%). However, the PDUFA fact rests on a single secondary source with no acceptance date, and Kalshi's persistent 26-37% range (drifting down over 7 days) is hard to reconcile with a publicly confirmed PDUFA nearly four months inside the window, so I assign meaningful weight to the scenario where the filing actually completes later in H2 2026 and the review clock lands near or past the cutoff (~35-40% Yes in that world). Blending these scenarios yields a moderate lean to Yes above the market anchor but below Forecast 2, and the critique's points on CRL base rates and major-amendment tail risk justify not going higher.

Pipeline Timing

Total pipeline time: 205.2s

Per-tool research timings shown in the Research section above.